Consort delivers good financial results with continuing organic growth in a transformational year.
Consort Medical plc (LSE: CSRT) (“Consort”, “Consort Medical” or the “Group”), a leading global drug delivery Contract Development and Manufacturing Organisation (“CDMO”), today announces its unaudited results for the year ended 30 April 2015.
Jon Glenn, Chief Executive Officer of Consort Medical, commented: “We have delivered good financial results in a transformational year for the Company. The acquisition of Aesica brings significant further know how and process technology to Consort’s range of pharma services. Bespak delivered another year of good organic growth and made marked progress with its growing pipeline. We are confident that the integration of Aesica will drive additional growth as the two businesses combine their expertise to provide joined-up development and supply chain solutions to meet customers’ needs. “The Board believes that the enlarged pipeline of opportunities and capabilities underpins its growth ambitions, and is confident of meeting its expectations for the coming financial year.”
Consort Medical plc
Tel: +44 (0) 1442 867920
Jonathan Glenn, Chief Executive Officer
Richard Cotton, Chief Financial Officer
Tel: +44 (0) 20 3727 1000
Ben Atwell / Simon Conway